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Conventionally,pathway-basedanalysisassumesthatgenes ina pathwayequally contribute to a biologicalfunction,thus assigning
uniform weight to genes. However, this assumption has been proved incorrect, and applying uniform weight in the pathway
analysis may not be an appropriate approach for the tasks like molecular classiﬁcation of diseases, as genes in a functional group
may have diﬀerent predicting power. Hence, we propose to use diﬀerent weights to genes in pathway-based analysis and devise
four weighting schemes.Weapplied them in two existing pathwayanalysismethods using both real andsimulated gene expression
data for pathways. Among all schemes, random weighting scheme, which generates random weights and selects optimal weights
minimizing an objective function, performs best in terms of P value or error rate reduction. Weighting changes pathway scoring
and brings up some new signiﬁcant pathways, leading to the detection of disease-related genes that are missed under uniform
weight.
1.Introduction
With the advent of microarray technology in the ﬁeld of
biomedical research [1–7], numerous statistical methods
[8, 9] were proposed to analyze microarray gene expression
data. But most are single gene based and do not consider the
interacting relationship or dependencies among genes in a
functional group. In single gene-based analysis, most subtly
but coordinated diﬀerentially expressed genes are often not
identiﬁed assigniﬁcant and usually droppedby a strict cutoﬀ
threshold feature selection [10, 11]. In contrast, pathway-
based analysis considers a set of biologically related genes
and helps detect subtle changes in gene expression with the
help of a joint eﬀort by genes [3, 4, 12, 13]. Many researchers
discussed the advantages of pathway-based analysis. Sub-
ramanian, for instance, considered an enrichment-based
approach using various Kolmogorove-Smirnov statistics [3];
Curtis gave a good review of computational approaches
proposed for pathway-based analysis [4]; Goeman et al.
proposed the global test based on a generalized linear model
[12]; Pang et al. described the random forest-based pathway
analysis [13];Harris etal.consideredgenegroupingbasedon
gene ontology [14]; Misman et al. provide good reviews on
those in [15].
A biological pathway is a series of actions among
molecules in a cell that leads to a certain product or a
change in a cell. Such a pathway can trigger the assembly
of new molecules, such as fat or protein. Pathways can
also turn genes on and oﬀ or spur a cell to move [16].
Biological pathways help researchers learn a lot about
human disease, since identifying genes, proteins, and other
molecules involved in a biological pathway can provide clues
about what goes wrong when a disease strikes. Researchers
may compare certain biological pathways in a healthy
person to the same pathways in a person with a disease to
discover theroots of thedisorder. Using pathways extensively
allows a quick overview of expression results in relation
to biological mechanisms, facilitating the understanding of
gene, protein, and metabolite interactions at higher levels.
Over the past decade, researchers have discovered many
important biological pathways through laboratory studies of
cultured cells and various organisms, and they are stored in
public domain biological pathway databases [16]. Biological
pathways have been also curated manually combining three2 Comparative and Functional Genomics
content sources: public domain databases, literature, and
experts [17].
Pathway analysis aims to deﬁne the meaning of biolog-
ical processes by identifying signiﬁcant pathways through
statistical evaluations. Pathways are scored in statistical
evaluations based on activity, coregulation, and cascade
eﬀects in pathways as measured by the gene expression levels
from the microarray experimental data. This score will rank
thosepath wayshigherinwhichmoregenesareoverexpressed
or underexpressed with reference to reference state [18].
Ranking pathways relevant to a particular biological process
or disease is useful, since it allows researchers to focus on
a smaller number of pathways for further study of the bio-
logical process or disease of interest. Most pathway analysis
tools and methods, however, are assuming that all genes in a
pathway are equally contributing to a biological process, and
thusassigning uniform weight. Butthis assumption has been
proved incorrect [19] because some genes may have higher
relevanciesto a particular biologicalprocess, and those genes
presumably have higher predicting or classifying power than
the others. One issue in the pathway analysis is the quality
of pathways since biological pathway databases are not
comprehensive, and the biological pathway content varies
greatly in quality and completeness among the tools and
databases [17]. Pathway data taken from public databases
and open literatures may include nonrelevant genes and/or
exclude relevant genes [20]. For instance, in the case of the
famousMootha’stypeIIdiabetespathwaydataset[21],genes
such as CAP1, MAPP2K6, ARF6, and SGK contained in the
pathway ID 36, c17 U133 probes, are known to be related to
human insulin signaling [15], while other genes are not yet.
Also, SHC contained in the pathway ID 229 is known to be
related to human insulin signaling, while others are not yet.
To address the problem of pathway quality and incom-
pleteness in the pathway analysis tools and approaches,
some researchers tried to minimize the misspeciﬁcations
by deﬁning signature genes to represent pathway behaviors,
and/or reﬁning pathways to adapt to speciﬁc conditions
by removing unaltered genes from the dataset [19, 22–24].
Others tried to improve the functional interpretation of
gene groups by including additional information associated
with the group [24]. Joining such eﬀorts, we propose to
applynonuniform weighting scheme, which appliesdiﬀerent
weights to the genes in a pathway-based on the relevancies
of genes to a related biological process or disease. The
intuitive ideas behind our proposed ideas are that not all
genes grouped in a pathway are related to a particular
biological process or disease with the same signiﬁcance,
and thus applying weight to the genes proportional to their
relevancies to a certain biological process or disease may
generate more accurate results for pathway based analysis
such as the molecular classiﬁcation of diseases.
To investigate the impact of using weighting schemes in
pathway based analysis, we devise four diﬀerent weighting
schemes and incorporate them into the existing pathway
analysis methods, such as the global test [12]a n dt h e
random forests [13, 25–27]. Our schemes essentially apply
largerweights to more diﬀerentially expressed genesbetween
diﬀerent sample groups (i.e., normal vs. tumor samples),
so those genes impact more on the ﬁnal results of analysis.
T h ef o u rw e i g h t i n gs c h e m e sw ei n t r o d u c ei nt h i sp a p e r
are as follows. The ﬁrst weighting scheme is based on the
absolute value of two sample t statistics denoted as absT.
The second one is based on the Q test statistic of the global
test denoted as Qdiﬀ. The third and the fourth ones are
based on a computational approach, which assigns weights
randomly to genes and selects optimal weights minimizing
anobjectivefunction.ThethirdschemecalledRWV (random
weight vector) is to assign m weights for m genes, in which all
s a m p l e so fag e n ea r ea s s i g n e dt h es a m ew e i g h t .T h ef o u r t h
onecalledRWM (random weight matrix) istoassign amatrix
of weights for a pathway of m(genes) ×n(samples), in which
samples of a gene are assigned diﬀerent weights.
We performed ourexperiments using the type IIdiabetes
dataset obtained from Mootha et al. [28]a n dt h ec a n i n e
dataset from Enerson et al. [29]. We also used simulated
datasets to gain an in-depth understanding of weighting
eﬀects in a controlled way. In our experiments, we apply
each weighting scheme onto the datasets and select top 20
or 33 signiﬁcant pathways. We evaluate the performance of
our weighting schemes by comparing the P values of the
pathways selected using each scheme with those selected
using uniform weighting. We observe that when our weights
a r ea p p l i e d ,t h es c o r i n go ft h ep a t h w a y si sc h a n g e d ,a n d
some pathways originally in lower ranks are elevated to
higher ranks, hence, contributing to improved prediction
rates. According to the previous studies [28, 30–34], several
signiﬁcant pathways identiﬁed by our weighting schemes are
biophysiologically associated with related diseases.
2.Materialsand Methods
2.1. Global Test and Random Forest. We used the global
test [12] and the random forests [13, 25, 26]m e t h o d st o
investigate the impact of weighting in the pathway-based
analysis and to evaluate the performance of our weighing
schemes. First, we review the two methods brieﬂy to explain
how we incorporate our proposed weighting schemes into
these methods.
2.1.1. Overview of Global Test. The global test method is a
pathway analysis method developedby Goeman et al. [12]. It
tests whether subjects with similar gene expression proﬁles
have similar class labels, based on a logistic regression.
Suppose that gene expression data containing n samples
for p genes is normalized. Of these p genes, a subgroup
of m (1 ≤ m ≤ p) genes is to be tested. Let X =
(xij)b ea nn × m data matrix containing m genes for n
samples of interest, and Yi as the clinical outcome of the ith
sample (n × 1vector). To model how the clinical outcome
Y depends on the gene expression data X, the global test
adoptsthegeneralized linear model framework developedby
McCullagh [35], expressed as follows:
E
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⎛
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where βj is the regression coeﬃcient for gene j (j =
1,...,m), h is a link function (e.g., the logit function), and
α is an intercept. Testing a predictive eﬀect of the gene
expressions on the clinical outcome is equivalent to testing
the hypothesis H0 : β1 = β1 = β2 ··· = βm = 0.
Assume that β1,...,βm are a sample from some common
distribution with zero mean and variance τ2,t h e nas i n g l e
unknown parameter τ2 determines the allowed deviation
of the regression coeﬃcients from zero. Thus, the null
hypothesis is H0 : τ2 = 0. The formula ri =
 
j xijβj (i =
1,...,n) is the linear predictor, that is, the total eﬀect of all
covariates for the i th sample. As r = (r1,...,rn)i sar a n d o m
vector with E(r) = 0a n dc o v ( R) = τ2XX ,t h eg e n e r a l i z e d
linear model is simpliﬁed to E(Yi | β) = h−1(α + ri). A test
statistic for testing H0 is deﬁned as
Q =
1
μ2
n  
i=1
m  
j=1
Rij
 
Yi − μ
  
Yj − μ
 
,( 2 )
where R = (1/m)XX  is an n × n matrix proportional to
the covariance matrix of the random eﬀects r, μ = h−1(α)
is the expectation of Y under H0,a n d( Y − μ)(Y −μ)
  is the
covariance matrix of the clinical outcomes of the samples.
The test statistic Q has a higher value if the terms of the
two matrices are correlated more. Essentially, it tests whether
samples with similar gene expressions also have similar
outcomes.TheempiricaldistributionofteststatisticQ under
the null hypothesis H0 is calculated across all samples by
randomly taking a large number of permutations (such as
100,000) of the vector Yfrom the outcomes. The empirical
P value is the frequency such that Q for the permuted Y
is at least as large as the true Q,d i v i d e db yt h en u m b e ro f
permutations. For our microarray datasets cases, Y is 1 for a
disease sample or 0 for a normal sample.
The reason we selected the global test pathway analysis
method for our study of weighting eﬀect in the pathway-
based analysis is that the generation and the assignment of
weightsforthegenesinapathwayiseasyandstraightforward
in the global test. Multiplying a desired nonuniform weight
matrix W = (wij) to a gene expression data matrix X = (xij)
in the global test method does not incur any side eﬀects.
2.2. Overview of Random Forests. The random forests are a
tree-based method developed by Breiman et al. (1984, 2001)
[25–27], which can be used for classiﬁcations or regressions
[13]. The method grows multiple classiﬁcation or regression
trees using a deterministic algorithm, in which each tree
is constructed using a diﬀerent bootstrap sample from the
original data. It leaves about one-third of the cases out of the
bootstrap (out-of-bag)samples fortesting purpose. The out-
of-bag (OOB) samples are not used in constructing the kth
tree but saved to be used as a test set. At the end of the run,
it takes the ith sample to be the class which receives most of
the votes every time case n is the out of bag. The proportion
of times that i i sn o te q u a lt ot h et r u ec l a s so fn averaged
over all cases is called the estimated out-of-bag (OOB) error
(http://stat-www.berkeley.edu/). Pang et al. [13]a r et h eﬁ r s t
group who proposed to apply the random forests approach
to pathway analysis, and we adopted their approach to study
the weighting eﬀect in the pathway analysis. Our objective is
toﬁndtheoptimalweight W∗ thatminimizes theOOBerror
rate using the objective function we modify in the following:
W
∗ = argmin
w
[F(wX)],( 3 )
where F(X) is the original cost function of the random
forests that computes the OOB error rate of a group of data
X,a n dw is a weight matrix for the group of data X.O u r
o b j e c t i v ei st oﬁ n dt h ew e i g h tm a t r i xw which minimizes the
estimated OOB classiﬁcation error for each pathway.
2.3. Proposed Weighting Schemes. We considered four
nonuniform weight schemes, which intend to generate the
w e i g h tf o re a c hg e n ei nap a t h w a y ,b a s e do ni t sd e g r e eo f
diﬀerential expression between the diﬀerent phenotypes. In
this section, we describe the rationale behind each weighting
scheme, generation, and assignment of nonuniform weights
for genes in a pathway.
2.3.1. absT Based on Two-Sample t-Test Statistic |T|. The
two-sample t-test statistic is widely used to determine if
the means of two populations are equal [35]. To measure
how diﬀerentially a gene is expressed between two diﬀerent
groups (i.e., normal versus disease), we calculate the two-
sample t-test statistic of the gene and take the absolute value
of it and denote it as |T|.T h eabsT scheme determines the
weight of each gene in a pathway using the |T| value of each
gene divided by the sum of all |T| values of all genes in the
pathway. Mathematically, the weight for the jth gene W|T|
(j)
is expressed in the following formula:
W
|T|
(j) =
     T(j)
     
 m
j=1
     T(j)
     
. (4)
With this scheme, the most diﬀerentially expressed gene will
have the largest |T| value and get the largest weight. The
rationale is based on the hypothesis that more diﬀerentially
expressed genes have higher relevancy to the disease or the
phenotype of interest.
2.3.2. Qdiﬀ Based on the Test Statistic Q of the Global
Test. The test statistic Q of the global test is a test to
ﬁnd whether samples with similar gene expressions also
have similar outcomes. If the covariance structure of the
gene expressions between two sample groups resembles the
covariance structure of their outcomes, the Q statistics is
large. The proposed Qdiﬀ weighting scheme uses the Q
statistic ofapathwaytoconstruct theweights forgenesinthe
pathway.Theideaisbasedonourhypothesisthatifexcluding
one gene from a pathway results in a large diﬀerence in the
original test statistic Q, the excluded gene may have a strong
relevancy to the related disease or phenotype. To determine
the weight for the jth gene in a pathway containing m genes,
the scheme uses the following formula:
W|Qdif f |
(j) =
     Q − Q(−j)
     
 m
j=1
     Q − Q(−j)
     
. (5)4 Comparative and Functional Genomics
Here, Q is the test statistic of the pathway including all m
genes, and Q(−j) is the test statistic of the same pathway
but excluding the jth gene. The weight of the jth gene is
determinedby thediﬀerenceofthese twotest statisticsQ and
Q(−j),dividedbythesumofallsuchdiﬀerencescalculatedfor
all m genes in the pathway.
2.3.3. RWV Based on Random Weight Vectors Generated
by a Computational Approach. The computational RWV
(random weight vector) scheme assigns m random weights to
m genes in a pathway and identiﬁes the optimal m weights
vector minimizing the P value of the pathway. It uses the
following pseudocode algorithm to obtain the optimal m
weights vector for each pathway.
Step 1. Run the global test on the original gene expression of
a pathway and obtain the P-value for the pathway. Initialize
this P-value as minP and the uniform weight vector as optW.
Step 2. for i = 1: COUNT.
Substep 1. Generate a set of m random values in the pre-
deﬁned range (i.e., 0.1 ≤ range ≤ 1.0).
Substep2. Pickm valuesrandomly fromtheset ofmrandom
values constructed in Substep 1, allowing replacements.
Substep 3. Multiply each gene expression Xj = [Xj,1,Xj,2,
...,Xj,n] with the corresponding weight wj (1 ≤ j ≤ m).
This process constructs a weighted gene expression matrix
wX for the pathway
wX =
⎡
⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢
⎣
w1X1
w2X2
. . .
wmXm
⎤
⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥
⎦
. (6)
Substep 4. Run the global test on the weighted gene expres-
sion matrixwX of the pathway and obtain P-value.
Substep 5. If the P value of the weighted gene expression
matrix wXobtained in Substep 4 is smaller than the current
minP, update the minP with this P value and update the
optimal weight vector optW with the new w = [w1,w2,
...,wm]c o n s t r u c t e di nS u b s t e p2.
End (for loop). Of course, the larger number of iteration
increases the quality of the solution, but at the cost of higher
computation time. We should also note that this weighting
scheme assigns the weight to each gene across all samples as
absT and Qdiﬀ schemes do.
2.3.4. RWM Based on Random Weight Matrices Generated by
a Computational Approach. In contrast to the three schemes
assigning thesame weight acrossallsamples foragene,RWM
(random weight matrix) scheme assigns diﬀerent weights
to all samples for a gene. Essentially, RWM scheme uses
the same algorithm of RWV scheme except that it generates
n × m random values instead of m random values, for the
n samples in the pathway of m genes. The n × m random
values in the predeﬁned range are multiplied to the n × m
gene expression data. Among all sets of random weights it
applied, the scheme selects an optimal set of weights that
minimizes the P-value in the global test, or the OOB error
rate in the random forests for the pathway. The weighted
gene expression matrix wX of a pathway is expressed in the
following matrix:
wX =
⎡
⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎣
w1,1X1,1 w1,2X1,2 ... w1,mX1,m
w2,1X2,1 ... ... w2,mX2,m
... ... ... ...
wn−1,1Xn−1,1 ... ... wn−1,mXn−1,m
wn,1Xn,1 wn,2Xn,2 ... wn,mXn,m
⎤
⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎦
. (7)
Obviously, RWM scheme can ﬁnd a better solution in
minimizing theP-valueortheOOBerrorthanRWV scheme,
but it is computationally more complex.
2.4. Datasets
Real Datasets. The ﬁrst real dataset we used for our
s t u d yi st h ew e l l - k n o w nt y p eI Id i a b e t e sm i c r o a r r a yg e n e
expression dataset obtained from Mootha et al. [28], con-
sisting of 278 pathways for 13,842 genes, sampled from
26 people with type II diabetes and 17 without. The
pathways were obtained from KEGG pathway database
(http://www.genome.jp/kegg/pathway.html), and the curate
pathways were constructed from known biological experi-
ments performed by Mootha et al. Another real dataset we
used is the canine dataset obtained from Enerson et al. [29],
consisting of 441 pathways for 6,592 genes, sampled from
12 dogs with lesion and 17 without. The canine dataset was
generated from the investigative toxicology studies designed
to identify the molecular pathogenesis of a drug-induced
vascular injury in coronary arteries of dogs, which were
treated with adenosine receptor agonist CI-947. The canine
genes were mapped to human orthologs, and the human
orthologs for dogs were generated by matching the genes
sequence using BLASTx [13, 29]. Note that not all genes
in a pathway have the same signiﬁcant relevancies to the
related disease. Some genes in a pathway could be related
more signiﬁcantly to the disease and some genes less or not
at all. The pathway ID 36 in the type II pathway dataset, for
i n s t a n c e ,c o n t a i n ss e v e r a lg e n e ss u c ha sC A P 1 ,M A P P 2 K 6 ,
ARF6, and SGK, which are known to be related to the
human insulinsignaling, while containingothergeneswhose
relevancies to the type II diabetes are not known yet [21].
Simulated Datasets. To study the weighting eﬀect with
more control, we created two simulated datasets using
the simulator function available in the boost R package,
which allows a simulated data to retain the same mean
and the same correlation structure of the original pathway
data [13, 36]. As the basis of our simulations, we selectedComparative and Functional Genomics 5
two real pathways containing more than 20 genes and
generating high P value in the global test or high OOB
error rate in the random forests under uniform weight, to
manifest the weighting eﬀect more clearly. One pathway
is “MAP00480 Glutathione metabolism,” ID 164 from the
type II diabetes dataset, containing 26 genes, ranked in the
277th with P-value 0.95 in the global test. Another pathway
is “Eicosenoid Metabolism,” ID 441 from the canine dataset,
containing 21 genes, ranked in the 421st with out-of-bag
(OOB) error rate 0.48% in the random forests. For both
cases, we used the multivariate normal distribution to create
thesimulatedpathwaydataforsamplesize of30,50,and100,
withnormalanddiseasegroupassignedwithevennumberof
samples.
3.Resultsand Discussion
We applied each proposed weighting scheme on each dataset
in the global test and ranked the pathways in the increasing
order of P values obtained from the global test. From the
ordered list of pathways for each output set, we selected
the top 20 pathways for our analysis. In the random forests
case, we only applied RWM scheme, since the other three
proposed schemes apply the same weight across all samples
for genes, and that does not change the outcome of the out-
of-bag error calculations for the genes by the random forests
algorithm. For the random forest application results, we
selectedtop33pathwaysinsteadof20,intheincreasing order
of OOB error rates, to include the multiple pathways tied in
some ranks within the 20th. Ranking pathways is important
in the pathway analysis because it enables researchers to
focus on a small number of pathways, which are estimated
as statistically signiﬁcant in terms of the relationship to
the disease or phenotype of interest. In this paper, we
focus on the top 20 or 33 selected pathways groups for
each weighting scheme for the performance analysis of
the proposed schemes and the comparison of them to the
performance of uniform weight.
For the greed search for the optimal set of weights
in the applications of RWV and RWM schemes, we used
25,000 iterations, since our experiments on the type II
diabetes dataset in the global test showed no meaningful
decrease in the P values, for the iterations of 20,000 or
greater.TheaverageP-values ofthetype IIdiabetespathways
corresponding to diﬀerent number of iterations for running
RWM scheme in the global test are displayed in Figure 1.
To help readers refresh the memory of our four proposed
weighting schemes before we discuss the application results
ofthose in the following sections, we provide a briefsumma-
ry of the four schemes in Table 1.
3.1. The Global Test Application Results
3.1.1. Reduction of P Values
Type II Diabetes Dataset. The pathway identiﬁcation num-
bers (PID) of the type II diabetes pathways in all top 20
groups are displayed in Table 2.W h i l et h ea v e r a g eP-value
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Figure 1: Average P-value of all Type II diabetes pathways versus
number of iterations for RWM in the global test.
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Figure 2: P-value distributions for the top 20 Type II diabetes
pathways selected by each weighting scheme in the global test.
of the 20 pathways under uniform weight is 0.0612, it is
much smaller under the proposed weighting schemes. In
terms of the P value reduction, RWM performed best (with
the average P-value of.0001), followed by absT (.0007), Qdiﬀ
(.0027), and RWV (.0044). The amounts of reduction are
ranged from.0611 for RWM to.0568 for RWV.A sa n o t h e r
metric to examine the impact of our weighting schemes, we
counted the total number of pathways having P-value less
than 0.05. Among all 278 pathways in the dataset, RWM
yields the largest number (=264) of pathways with P-values
less than.05, followed by absT (with 142), Qdiﬀ (with 74),
RWV (with 66), and uniform weight (with 8). Those results
reveal that our schemes eﬀectively reduce the P-values of
the pathways compared to the uniform weight. The statistics6 Comparative and Functional Genomics
Table 1: A brief summaryof the four proposed weighting schemes. The algorithmsare expressed for the pathway ofm genes and n samples.
absT andQdiﬀ algorithmscalculatetheweightforthe jth geneinapathway,andRWV selectsanoptimalrandomweightvectorw minimizing
P-value or OOB error rate, and RWM selects an optimal weight matrix w minimizingP-value or OOB error rate.
Name Algorithm Notes
absT W|T|
(j) =| T(j)|/
 m
j=1 |T(j)|
Based on two-sample t statistics of a gene,
apply the same weight across all samples of a
gene
Qdiﬀ W
|Qdif f |
(j) =| Q −Q(−j)|/
 m
j=1 |Q −Q(−j)|
Based on the global test statistic Q for a
pathway, apply the same weight across all
samples for a gene
RWV (Random
Weight Vector)
wX =
⎡
⎢
⎣
w1X1
w2X2
. . .
wmXm
⎤
⎥
⎦
m number of random weights in predeﬁned
range that minimizes P-value in the global
test, or OOB error rates in the random
forests for a pathway
RWM (Random
Weight Matrix)
wX =
⎡
⎢ ⎢ ⎣
w1,1X1,1 w1,2X1,2 ... w1,mX1,m
w2,1X2,1 ... ... w2,mX2,m ... ... ... ...
wn−1,1Xn−1,1 ... ... wn−1,mXn−1,m
wn,1Xn,1 wn,2Xn,2 ... wn,mXn,m
⎤
⎥ ⎥ ⎦
m ×n number of random weights in
predeﬁned range that minimizes P-value in
the global test or error rates in the random
forests for a pathway
0
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Figure 3: P-value distributions for the canine pathways selected by
each weighting scheme in the global test.
of the P-value distributions for all 20 pathways groups are
s h o w ni nt h eb o xp l o t si nF i g u r e2.I nt e r m so ft h eP values,
RWM is the best followed by absT,a n du n i f o r mw e i g h ti st h e
worst. The dispersion of P values for uniform weight is the
widest among all with largest number of outliers.
Canine Dataset. According to the pathway analysis per-
formed by Pang et al., the canine dataset has a relatively
large number of diﬀerentially expressed genes [13]. We were
interested in the performance of the proposed weighting
schemes for such a dataset. The 20 pathways groups for
all weighting schemes are displayed in Table 3.T h ea v e r a g e
P-value of the 20 pathways for uniform weight is.00015,
but it is also smaller for our weighting schemes. In terms
of the P value reduction, the best performing scheme is
RWM (with average P-value of.00001), followed by absT
(.00002), RWV (.00002), and Qdiﬀ (.00012). The reduction
amounts are ranged from.00014 for RWM to 0.00003 for
Qdiﬀ. Compared to the type II diabetes pathways results, the
reduction amount for the canine pathways are smaller. Such
result is not unexpected, since the canine dataset is known
to have more diﬀerentially expressed genes and may leave
smaller room to improve. Among all 441 pathways in the
dataset, RWM has the largest number (=431) of pathways
having P value less than.05, followed by absT (with 405),
RWV (with 388), uniform weight (with 204), and Qdiﬀ
(with 170). Our weighting schemes except Qdiﬀ double
t h en u m b e ro fp a t h w a y sw i t hP values less than.05. It is
rather interesting that Qdiﬀ improves the P values of the 20
pathways over the uniform weight but decreases the number
of total pathways with P values less than.05. The P value for
all20pathwaysgroupsareshown inthebox-plotsinFigure3.
In terms of P-values, RWM and RWV are best followed by
absT, and uniform weight and Qdiﬀ are worst. The P values
for RWM and RWV are similar, but RWM is better in terms
of outliers.
Simulated Datasets. Upon our observation that RWM per-
forms best in terms of P-value reduction, we applied RWM
scheme on our simulated data to study the P value reduction
in a more controlled environment. The P values of all
simulated pathway data under uniform weigh and RWM
scheme are given in Table 4. In the simulation case 1,
the P values of the simulated pathways with 26 genes
for 30, 50, and 100 samples were.2246,.2155, and.2573,
respectively, under uniform weight (in Table 4(a)), but
reduced to.0014,.0007, and.0002, respectively, under RWM
scheme (in Table 4(b)). In the simulation case 2, the P
values of the simulated pathways with 21 genes for 30 and 50
sampleswere.0289and.0004underuniformweight,but.0002
and.0001,respectively underRWM scheme. However,for the
sample size 100 data, the P-value was zero under uniform
weight, and no further improvement was by the RWM.Comparative and Functional Genomics 7
Table 2: Top 20 type II diabetes pathways selected in the global test under each weighting scheme (PID stands for pathway identiﬁcation
number).
Weighting schemes
Uniform absT Qdiﬀ RWV RWM
Ranks PID P-value PID P-value PID P-value PID P-value PID P-value
1 158 .0098 40 .0002 140 .0004 140 .0003 195 .0000
2 264 .0114 140 .0003 57 .0008 92 .0006 172 .0000
3 140 .0218 13 .0003 41 .0015 139 .0009 127 .0001
4 4 .0331 37 .0004 4 .0017 4 .0011 2 .0001
5 228 .0431 57 .0005 264 .0018 264 .0015 76 .0001
6 168 .0474 44 .0006 158 .0018 158 .0015 235 .0001
7 73 .0503 92 .0006 20 .0018 157 .0022 199 .0001
8 139 .0509 278 .0006 157 .0018 20 .0024 198 .0001
9 204 .0555 66 .0007 193 .0018 228 .0028 261 .0001
10 92 .0618 56 .0007 26 .0019 203 .0035 277 .0001
11 162 .0625 51 .0007 92 .0027 26 .0048 158 .0001
12 203 .0746 109 .0007 232 .0035 17 .0049 80 .0001
13 229 .0784 139 .0008 37 .0036 193 .0064 263 .0001
14 201 .0817 104 .0009 58 .0040 73 .0066 19 .0001
15 120 .0823 4 .0010 59 .0040 208 .0069 165 .0001
16 76 .0831 217 .0010 60 .0040 8 .0073 42 .0001
17 128 .0847 110 .0010 61 .0040 79 .0077 144 .0001
18 274 .0937 43 .0010 62 .0040 16 .0078 162 .0001
19 247 .0968 36 .0011 63 .0040 252 .0090 258 .0001
20 22 .1015 228 .0011 139 .0049 173 .0093 1 .0001
Total P-values 1.2244 .0142 .0540 .0875 .0018
Average P-value .0612 .0007 .0027 .0044 .0001
3.1.2. Change of Ranks and New Signiﬁcant Pathways. Our
weighting schemes reduce P values of most pathways in
each dataset and hence change the ranks of the pathways
determinedbytheuniform weight. So,somepathways in low
ranks under the uniform weight improve their rankings and
maydrawresearchers’attention.Wedescribeafewsuchcases
in the following.
Type II Diabetes Dataset. We observed ﬁve pathways with
pathway identiﬁcation numbers (PIDs) of 13, 43, 51, 66, and
109 under absT scheme are originally ranked in the 107th or
below under uniform weight. Interestingly, these pathways
arereportedtobeassociatedwiththetypeIIdiabetesinsome
ways in a couple of papers [37, 38]. The names, ranks, and P
values of those pathways under uniform and absT scheme
are given in Table 5. Such low ranking pathways might have
beenignored by researchers underthe uniform weight, while
they would draw researchers’ attention with our weighting
schemes.
Canine Dataset. Six canine pathways with PIDs of 133, 154,
156, 320, 375, and 420 under absT scheme are originally
ranked in the 258th or below under uniform weight. The
associations of these new identiﬁed signiﬁcant pathways to
the cancer-related disease are also reported in several papers
[39, 40, 40]. The names, ranks, and P values of those
pathways under absT scheme are compared to those under
uniform weight in Table 6. We observe similar impacts on
pathway ranks induced by our other weighting schemes.
They are not reported here to conserve space, but available
in the ﬁrst author’s technical report.
3.1.3. Overlapping Pathways. While those newly identiﬁed
signiﬁcant pathways under would draw researchers’ fresh
attentions, pathways identiﬁed as signiﬁcant repeatedly
under multiple weighting schemes may worth additional
attention by researchers. We observed that several pathways
hold high rankings across diﬀerent weighting schemes, and
their biological associations to the related diseases are dis-
cussed in numerous reports. We indicated those overlapping
pathways appearing in three or more weighting schemes in
bold faces in Tables 2 and 3. We discuss them in more detail
for the two datasets in the following.
Type II Diabetes Dataset. Overlapping pathways among
the top 20 groups include Alanine and aspartate
metabolism (PID = 4), Glutamate metabolism (PID =
92), MAP00252 Alanine and aspartate metabolism (PID
= 140), MAP00430 Taurine and hypotaurine metabolism
(PID = 158), Oxidation Phosphorylation (PID = 228),8 Comparative and Functional Genomics
Table 3: Top 20 canine pathways selected in the global test under each weighting scheme (PID stands for pathway identiﬁcation number).
Weighting schemes
Uniform absT Qdiﬀ RWV RWM
Ranks PID P-value PID P-value PID P-value PID P-value PID P-value
1 117 .00003 151 .00000 368 .00003 17 .00000 39 .00000
2 39 .00004 391 .00000 39 .00004 391 .00000 40 .00000
3 394 .00004 326 .00001 217 .00006 368 .00001 223 .00001
4 217 .00007 360 .00001 394 .00007 117 .00001 160 .00001
5 304 .00007 73 .00001 73 .00007 151 .00001 295 .00001
6 183 .00008 117 .00002 304 .00007 202 .00001 304 .00001
7 40 .00009 39 .00002 247 .00007 39 .00001 283 .00001
8 440 .00009 156 .00002 40 .00008 175 .00001 217 .00001
9 159 .00011 133 .00002 440 .00008 210 .00002 387 .00001
10 17 .00015 217 .00002 117 .00010 247 .00002 64 .00001
11 151 .00017 94 .00002 183 .00010 394 .00002 421 .00001
12 45 .00017 375 .00002 157 .00010 239 .00002 135 .00002
13 391 .00017 40 .00002 64 .00011 45 .00002 129 .00002
14 368 .00018 261 .00002 159 .00015 100 .00002 374 .00002
15 192 .00018 192 .00002 45 .00018 310 .00002 165 .00002
16 261 .00019 154 .00002 261 .00020 326 .00002 183 .00002
17 87 .00025 157 .00003 151 .00020 304 .00003 265 .00002
18 422 .00028 420 .00003 391 .00020 281 .00003 20 .00002
19 223 .00032 320 .00003 17 .00020 360 .00003 397 .00002
20 354 .00039 422 .00003 192 .00025 336 .00003 17 .00002
Total P-values .00307 .00037 .00236 .00034 .00027
Average P-value .00015 .00002 .00012 .00002 .00001
Table 4: Global test results on simulated datasets under RWM scheme and uniform weight: (a) simulation case 1 uses covariance structure
andmeanofPathwayID 164from type IIdiabetes dataset,(b) simulationcase2uses covariancestructure andmeanofPathwayID 441from
canine dataset.
(a) SimulationCase 1.
No. of samples No. of genes No. of tested Statistic Q Expected Q sd-of-QP values
Unif RWM Unif RWM Unif RWM
30 26 26 13.51 27.68 10 7.64 3.96 0.2246 0.0014
50 26 26 13.42 27.49 10 6.59 3.61 0.2155 0.0007
100 26 26 12.33 27.44 10 6.60 3.25 0.2573 0.0002
(b) SimulationCase 2.
No. of samples No. of genes No. of tested Statistic Q Expected Q sd-of-QP values
Unif RWM Unif RWM Unif RWM
30 21 21 34.60 46.51 10 9.46 5.57 0.0289 0.0002
50 21 21 66.41 56.91 10 7.94 5.87 0.0004 0.0001
100 21 21 97.11 70.69 10 8.03 5.42 0.0000 0.0000
and presented in bold faces in Table 2.A m o n gt h e m ,
oxidation phosphorylation (PID = 228) and glutamate
metabolism (PID = 92) are well known type II diabetes
pathways[28, 31].Alanine and aspartate metabolism
(with PID = 4), glutamate metabolism (PID = 92),
MAP00430 Taurine and hypotaurine metabolism (PID =
158), MAP00252 Alanine and aspartate metabolism (PID
= 140), and Alanine and aspartate metabolism (PID = 4)
are also reported to be strongly associated with the type II
diabetes in some ways by some researchers [31, 41, 42]. It is
interesting to notice that pathways of PIDs 4 and 140 retain
the high ranks (4th or above) across three diﬀerent schemes.
Canine Dataset. Androgen and estrogen metabolism (PID =
17),tryptophanmetabolism(PID=39),multistepregulation
of transcription by Pitx (PID = 117), RNA polymerase IIIComparative and Functional Genomics 9
Table 5: Five new signiﬁcant type II diabetes pathways selected in
the global test under absT scheme: P values and ranks of them are
compared to those under uniform weight.
Pathway name
P-values Ranks
Uniform absT Uniform absT
(PID = 13)
Apoptosis .3658 .0003 111 2
(PID = 66) Cell
cycle .4871 .0007 155 9
(PID = 51)
c3 U133 probes .3822 .0007 116 9
(PID = 109)
Integrin-mediated
cell adhesion
.3876 .0007 119 9
(PID = 43)
c22 U133 probes .3599 .0010 107 15
Table 6: Seven new signiﬁcant canine pathways selected in the
global test under absT scheme: P values and ranks of them are
compared to those under uniform weight.
Pathway name
P-values Ranks
Uniform absT Uniform absT
(PID = 133) Activation
of Csk by
cAMP-dependent
protein kinase inhibits
signaling through the T
cell receptor
.1006 .00002 258 6
(PID = 156) Steps in the
glycosylation of
mammalianN-linked
oligosaccarides
.1308 .00002 278 6
(PID = 375)
PTEN-dependent cell
cycle arrest and
apoptosis
.4451 .00002 371 6
(PID = 154) TPO
signaling pathway .5504 .00002 389 6
(PID = 420) Trefoil
factors initiate mucosal
healing
.2226 .00003 330 17
(PID = 320) CDK
regulation of DNA
replication
.5563 .00003 390 17
transcription (PID = 151), mitochondrial carnitine palmi-
toyltransferase system (PID= 217),and Rho cell motility sig-
naling pathway (PID = 391) are overlapping among diﬀerent
weighting schemes. Among them, tryptophan metabolism
(PID = 39)and mitochondrial carnitine palmitoyltransferase
system (PID = 217) hold the 8th or higher ranks, and the
biological signiﬁcance of the two pathways to lesions or
cancerous lesions are discussed by many researchers [32–34,
43–46, 46]. Biological associations of the other overlapping
pathways to the related disease are also discussed in some
reports [47, 48, 48].
Table 7:Predictionratesoftop20typeIIdiabetes pathwaysselected
in the global test under each weighting scheme.
Prediction
methods Uniform absT Qdiﬀ RWV RWM
LDA 0.57 0.58 0.53 0.55 0.81
SVML 0.61 0.59 0.58 0.61 0.79
SVMP 0.51 0.53 0.51 0.53 0.74
KNN 0.55 0.68 0.53 0.59 0.76
Table 8: Prediction rates of top 20 canine pathways selected in the
global test under each weighting scheme.
Prediction
methods Uniform absT Qdiﬀ RWV RWM
LDA 0.84 0.82 0.86 0.86 0.86
SVML 0.86 0.86 0.86 0.86 0.86
SVMP 0.71 0.70 0.72 0.72 0.70
KNN 0.84 0.83 0.83 0.84 0.87
3.1.4. Prediction Performances. Prediction rates are another
metric we used to measure the performances of our weight-
ing schemes. Using LDA (linear discriminator analysis),
SVML (support vector machine with a linear kernel),
SVMP (support vector machine with a polynomial kernel),
and KNN (k-nearest neighbors) classiﬁcation methods, we
measured the prediction performance of all genes in a
pathwayand taketheaverageofitforall pathwaysinthose20
groups and cross validated those classiﬁcation results using
the LOOCV (leave-one-out cross validation) technique. The
prediction performances of the pathways in all 20 groups are
presented in Tables 7 and 8 for the two datasets.
As we can see in the Tables 7 and 8,h o w e v e r ,t h ep r e -
dicting power of those pathways selected under the proposed
weighting scheme (except RWM) shows insigniﬁcant dif-
ference between those selected under uniform weight. This
explains that those classiﬁers we used for the performance
measurement are single gene based and do not consider
gene’s dependencies in the pathway. Since our weighting
schemes, except RWM, apply the same weight across all
groups of samples for each gene, the classifying power of
the genes do not change. Hence, those classiﬁers cannot be
used to evaluate the improvement of predicting power of
the pathways selected using our weighting schemes. Note
that unlike other schemes, RWM applies diﬀerent weights
to all samples for a gene, and thus the classiﬁers measure
the weighting eﬀect on the samples for each gene but not
on the genes in the pathways. We discuss the improvement
of predicting power only for the 20 pathways selected under
RWM scheme.
Table 6 shows the improvement of the predicting power
of the genes in the 20 type II diabetes pathways selected
under RWM scheme. The prediction rate 0.5 measured by
LDA for 20 pathways for uniform weight was increased to
0.81 for RWM, which is 24% improvement. The predic-
tion improvement made by RMW scheme was 18% when
measured by SVML, 23% by SVMK, and 21% by KNN. As10 Comparative and Functional Genomics
for the canine dataset results, the improvements were 2%,
0%, −1%, and 3% as measured by LDA, SVML, SVMP,
and KNN, respectively, as shown in Table VIII. The small
improvement for the canine pathways compared to that for
the type II pathways may share the same reason with the
small reductions of the P-values: the canine dataset to have
relatively more diﬀerentially expressed genes, and thus may
leave smaller room to improve.
3.2. Random Forests Results. The proposed absT and Qdiﬀ
weighting schemes are designed to incorporate into the
covariance structure of the random eﬀect R when the test
statistic Q is calculated in the global test for a group of
genes. Hence, the applicationof such schemes in the random
forests method is not appropriate, and indeed the poor
experimental results conﬁrmed it. RWV application in the
random forests is not appropriate either, since it assigns
the same weight across all samples for a gene like absT
and Qdiﬀ schemes. Thus, we only discuss the application
results of RWM scheme in the random forests method case,
and compare them with those of uniform weight. We also
compare those to the RWM application results in the global
test method.
3.2.1. Reduction of out-of-Bag (OOB) Error Rate. The out-
of-bag (OOB) error rate is the percentage of time that
the random forests classiﬁcation or regression is incorrect
for the OOB data. To obtain an unbiased estimate of the
classiﬁcation or regression error in the random forests, OOB
datarundownthetree,andtheoverallerrorrateiscomputed
when a speciﬁed number of trees are added to the forest.
We used 50,000 trees to estimate the classiﬁcation error, the
same number used in the similar experiments performed by
Pangetal.fortheirpathwayanalysisusingtherandomforests
method [13, 25–27].
Type II Diabetes Dataset. Table 9 displays the PIDs and the
OOB error rates of top 33 type II diabetes pathways in the
random forests under uniform weight and RWM scheme.
While the average OOB error rate under uniform weight is
35%, it is only 18% under RWM scheme. The OOB error
rate is reduced into almost a half by the application of RWM
scheme in the random forests.
Canine Dataset. T h ea v e r a g ee r r o rr a t e8 %u n d e ru n i f o r m
weight is reduced to 6% under RWM scheme, which is only
a half of the reduction made for the type II diabetes data
underRFM.T able10showsthePIDsandtheOOBerrorrates
o ft h e3 3c a n i n ep a t h w a y su n d e ru n i f o r mw e i g h ta n dRWM
s c h e m e .A g a i n ,al a r g e rn u m b e ro fd i ﬀerentially expressed
genes in the canine dataset may leave only a small room for
weighting to improve the application result.
Simulation Datasets. In the simulation case 1, the error rates
of the simulated pathways with 26 genes for 30, 50, and 100
samples are 0.27, 0.48, and 0.30, respectively, under uniform
weight and reduced signiﬁcantly to 0.13, 0.36, and 0.22,
respectively, under RWM scheme. In the simulation case 2,
the error rates of the simulated pathways with 21 genes for
30 and 50 samples are 0.50 and 0.30, respectively, under
uniform weight and reduced to 0.30 and 0.20 under RWM,
respectively. For the sample size of 100, the error rates were
same 0.24 for both uniform and RWM schemes. The OOB
error rates of simulated pathways under uniform and RWM
scheme are given in Table 11. The substantial reduction of
the error rates under RWM scheme over uniform weight
in the two simulation cases supports our hypothesis that
applying diﬀerent weights to genes in the pathway analysis
may enhance the quality of the analysis.
3.2.2. Change of Ranks and New Signiﬁcant Pathways. Four-
teen type II diabetes and ﬁve canine pathways out of each
33 group selected under RWM scheme are originally ranked
in the 100th or below under uniform weight. We list each
ﬁve most signiﬁcantly changed type II diabetes and canine
pathways in Tables 12 and 13, respectively, to compare their
original ranks under uniform weight to the new ranks under
RWM scheme
3.2.3. Overlapping Pathways. Three pathways with PIDs of 1,
4, and 140 from the type II diabetes dataset overlap between
uniform weight and RWM scheme. Nine canine pathways
with PIDs of 17, 39, 117, 151, 274, 354, 368, 378, and 395 for
the canine dataset overlap. Further, several pathways overlap
between the global test and the random forests application
results both under RWM scheme. Four type II diabetes
pathways with PIDs of 144, 176, 197, and 245 and ﬁve
canine pathways with PIDs of 17, 39, 40, 117, and 274 are
such pathways. Interestingly, the four canine pathways under
RWM scheme overlapping between the global test and the
random forests also overlap between uniform weight and
RWM scheme in the random forests. We believe that such
pathways overlapping across diﬀerent weighting schemes
applied in the same pathway analysis method, and across
diﬀerent pathway analysis methods for the same weighting
scheme, may have even stronger relevancies to the related
phenotypes.
3.2.4. Prediction Performances. The prediction rates of each
33 pathways group for each real dataset are given in Table 14.
According to the four classiﬁers we used to measure the
prediction rates of the selected pathways, RWM scheme
improved the prediction rate of the type II pathways from
52% to 63% (LDA), 48% to 64% (SVML), 49% to 54%
(SVMP), and 52% to 59% (KNN). But for the canine
pathways, it worsened the prediction rates. Presumably,
weights applied to the genes of good predicting power in the
signiﬁcant canine pathways may add noises to the expression
data of those genes and degrade the predicting power.
3.3.BiologicalSupport. Toinvestigatefurther thesigniﬁcance
of the proposed weighting scheme in terms of biological
meaning, we searched the functional annotations of the
genes in the selected pathways using weights. We particularly
sought the biological support for absT scheme, since our
overall performance analysis on our four proposed schemesComparative and Functional Genomics 11
Table 9: Top 33 type II diabetes pathways selected in the random forests under uniform weight and RWM scheme.
Index
Uniform weight RWM scheme
Rank PID No. of genes OOB (%) Rank PID No. of genes OOB (%)
1 1 79 33 0.26 1 140 22 0.11
22 4 18 0.29 2 113 26 0.14
32 140 22 0.29 2 192 1 0.14
4 4 36 116 0.31 4 106 5 0.17
5 4 124 4 0.31 5 117 26 0.17
6 4 230 121 0.31 4 144 70 . 1 7
77 5 60 . 3 441 6 380 . 1 7
8 7 16 49 0.34 4 164 26 0.17
9 7 32 157 0.34 4 176 3 0.17
10 7 46 36 0.34 4 197 11 0.17
11 7 51 185 0.34 4 235 3 0.17
12 7 109 91 0.34 4 244 46 0.17
13 7 141 4 0.34 4 245 11 0.17
14 7 229 133 0.34 4 250 12 0.17
15 7 267 4 0.34 4 251 1 0.17
16 16 1 2 0.37 4 254 25 0.17
17 16 6 3 0.37 4 274 16 0.17
18 16 11 15 0.37 4 275 9 0.17
19 16 13 92 0.37 19 1 20 . 2 0
20 16 37 235 0.37 19 4 18 0.20
21 16 40 240 0.37 19 5 60 . 2 0
22 16 49 188 0.37 19 11 15 0.20
23 16 59 194 0.37 19 24 14 0.20
24 16 76 3 0.37 19 42 2 0.20
25 16 144 7 0.37 19 52 122 0.20
26 16 162 2 0.37 19 69 20 0.20
27 16 173 11 0.37 19 74 1 0.20
28 16 194 13 0.37 19 78 6 0.20
29 16 201 19 0.37 19 80 5 0.20
30 16 207 3 0.37 19 85 8 0.20
31 16 209 21 0.37 19 86 39 0.20
32 16 227 13 0.37 19 98 71 0.20
33 16 228 43 0.37 19 99 13 0.20
Total 2050 11.29 578 5.86
Average 64 0.35 18 0.18
ﬁnds the absT is the most useful and eﬃcient requiring
no complex computation like RWM scheme. Using DAVID
functional annotation tool [49], we extracted 952 Homo
Sapiens genes from 2,150 genes contained the 20 pathways
selected under absT scheme. DAVID tool identiﬁed eleven
enriched genes associated with type II diabetes with P-
value.01 (by the gene-disease association search with GEN-
TIC ASSOCIATION DB DISEASE option). We list those
eleven genes in Table 15.
Interestingly enough, the DAVID tools failed to identify
any enriched genes for the type II diabetes in the top 20
pathways selected under uniform weight.
4.Conclusions
In this paper, we proposed to apply diﬀerent weighting
schemes in pathway-based analysis, based on our intuitive
thoughtthatgenesmorediﬀerentiallyexpressedbetweentwo
diﬀerent groups of samples (normal versus tumor samples)
will contribute more signiﬁcantly to the related biological
functionordisease.WedevisedfourweightingschemesabsT,
Qdiﬀ, RWV,a n dRWM that assign diﬀerent weights to genes
in the pathways. The former two schemes assign weights to
genes based on their relevancy to the related disease, and the
latter two schemes select the weights minimizing P-values
or error rates among all sets of weights randomly assigned.12 Comparative and Functional Genomics
Table 10: Top 33 canine pathways selected in the random forests under uniform weight and RWM scheme.
Index
Uniform weight RWM scheme
Rank PID No. of genes OOB (%) Rank PID No. of genes OOB (%)
11 274 40 . 0 31 39 90 . 0 0
21 354 60 . 0 32 17 80 . 0 3
31 378 15 0.03 2 45 40 0.03
41 395 14 0.03 2 182 5 0.03
55 17 80 . 0 722 2 070 . 0 3
65 73 50 . 0 72274 40 . 0 3
75 100 18 0.07 2 289 13 0.03
85 151 80 . 0 72354 60 . 0 3
95 239 90 . 0 72368 19 0.03
10 5 287 15 0.07 2 378 15 0.03
11 5 330 14 0.07 2 395 14 0.03
12 5 339 19 0.07 2 440 59 0.03
13 5 349 68 0.07 13 24 7 0.07
14 5 368 19 0.07 13 40 4 0.07
15 15 39 90 . 1 0 1 35 91 4 0 . 0 7
16 15 89 22 0.10 13 73 50 . 0 7
17 15 117 10 0.10 13 100 18 0.07
18 15 129 7 0.10 13 117 10 0.07
19 15 147 11 0.10 13 151 80 . 0 7
20 15 156 4 0.10 13 154 16 0.07
21 15 171 12 0.10 13 156 40 . 0 7
22 15 173 46 0.10 13 162 18 0.07
23 15 175 34 0.10 13 202 27 0.07
24 15 202 27 0.10 13 204 10 0.07
25 15 223 40 . 1 0 1 3223 40 . 0 7
26 15 230 3 0.10 13 229 6 0.07
27 15 280 17 0.10 13 234 8 0.07
28 15 281 32 0.10 13 239 90 . 0 7
29 15 289 13 0.10 13 264 15 0.07
30 15 326 11 0.10 13 269 7 0.07
31 15 380 25 0.10 13 280 17 0.07
32 15 391 7 0.10 13 326 11 0.07
33 15 436 6 0.10 13 330 14 0.07
Total 522 2.79 431 1.83
Average 16 0.08 13 0.06
Table 11: Random forests results for simulated datasets under uniform weight and RWM scheme: (a) simulation case 1 uses covariance
structure and mean of Pathway ID 164 from type II diabetes dataset, (b) simulation case 2 uses covariance structure and mean of Pathway
ID 441 from canine dataset.
No. of samples (a) SimulationCase 1 (b) SimulationCase 2
No. of
genes
OOB(%) No. of genes OOB(%)
Uniform RWM Uniform RWM
30 26 0.27 0.13 21 0.50 0.33
50 26 0.48 0.36 21 0.30 0.20
100 26 0.30 0.22 21 0.24 0.24Comparative and Functional Genomics 13
Table 12: Type II diabetes pathways whose ranks are signiﬁcantly changed under RWM in the random forests.
Pathway ID and name
Ranks OOB (%)
Uniform RWM Uniform RWM
PID 113 Limonene and pinene degradation 184 2 0.54 0.14
PID 106 Inositol metabolism 259 4 0.69 0.17
PID 164 MAP00480 Glutathione metabolism(user deﬁned) 242 4 0.63 0.17
PID 176 MAP00550 Peptidoglycan biosynthesis(user deﬁned) 259 4 0.66 0.17
PID 235 Peptidoglycan biosynthesis 259 4 0.66 0.17
Table 13: Canine pathways whose ranks are signiﬁcantly changed
under RWM in the random forests.
Pathway ID and name
Ranks OOB (%)
Uniform RWM Uniform RWM
PID 24 Alanine and
aspartate metabolism 319 13 0.34 0.07
PID 59 Glycerolipid
metabolism 242 13 0.28 0.07
PID 204 Role of PI3K
subunit p85 in
regulation of actin
organization and cell
migration
281 13 0.31 0.07
PID 229 Induction of
apoptosis through DR3
and DR4/5 death
receptors
157 4 0.21 0.07
PID 269 Ghrelin:
regulation of food
intake and energy
homeostasis
188 4 0.28 0.07
Table 14: Prediction rates of top 33 canine pathwaysselected in the
random forest under uniform weight and RWM scheme.
Prediction
methods
Type II diabetes dataset Canine dataset
Uniform RWM Uniform RWM
LDA 0.54 0.63 0.87 0.78
SVML 0.53 0.64 0.88 0.84
SVMP 0.46 0.54 0.76 0.72
KNN 0.54 0.59 0.80 0.73
We investigated the weighting impact in the pathway-based
analysis using two real and two simulated pathway datasets.
To our best knowledge, we are the ﬁrst team to apply weights
t og e n e si nt h ep a t h w a y - b a s e da n a l y s i si no p e nl i t e r a t u r e .
We made a few interesting observations through our
investigations. First, our weighting schemes eﬀectively
reduce P-values of the pathways in the global test and OOB
error rates in the random forests for all datasets used in
our experiments. Second, our schemes increase the number
of pathways with P- v a l u e sl e s st h a n0 . 0 5 .RWM performs
best among all proposed schemes in terms of P-value and
OOBerrorrate reduction,butthescheme iscomputationally
expensive. Third, RWM improves prediction rates of high
Table 15: Eleven genes associated with type II diabetes in the top
20 pathways selected under absT scheme.
Gene symbols Gene names
CD36 cd36 antigen (collagen type i receptor,
thrombospondin receptor)
CAS Caspase 9, apoptosis-related cysteine peptidase
GPX3 Glutathione peroxidase 3 (plasma)
GSTT1 Glutathione s-transferase theta 1
SOD1 Superoxide dismutase 1, soluble (amyotrophic
lateral sclerosis 1 (adult))
TPMT Thiopurine s-methyltransferase
GSTM1 Glutathione s-transferase m1
CYP2E1 Cytochrome p450, family 2, subfamily e,
polypeptide 1
LPL Lipoprotein lipase
TNF Lipoprotein lipase
GYS Tumor necrosis factor (tnf superfamily, member 2)
ranking pathways. Fourth, all the improvements discussed
above are more signiﬁcant for the type II diabetes dataset
than the canine dataset. It may be due to the fact that genes
with better predicting power ormore diﬀerentially expressed
leave less room for further improvement. In addition to
the above improvements, our schemes could ﬁnd potentially
signiﬁcant pathways which were missed by uniform weight.
As described in Section 3,p a t h w a y sw h o s er a n k si m p r o v e d
by weighting are associated to the related diseases according
to the reports presented in numerous literatures. Finally, it
is worth noting that absT and Qdiﬀ schemes are, in theory,
inferior to RWM scheme, but are computationally far less
complex than RWM. So, it may be a good idea to apply them
in case one as they cannot aﬀord large computing power or
long computing time.
We have unresolved issues for evaluating the weighting
eﬀect in the prediction performance of our proposed
schemes. The four prediction methods (LDA, SVML, SVMP,
and KNN) are single gene based and cannot be used to
evaluate our schemes absT, Qdiﬀ, and RWV.I nt h ep e r -
spective of those methods, the same weight assigned across
all samples of a single gene does not make any change in
terms of classifying two diﬀerent groups of samples for that
single gene. Even for RWM scheme, they only can evaluate
the weighting eﬀect on samples but not on genes, since they
cannot consider the interactive relationship or dependencies14 Comparative and Functional Genomics
among genes in a group. It is necessary to develop a new
prediction method that considers the dependencies among
genesformoreaccurateassessment ofweightingeﬀectsinthe
pathway-based analysis. Developing such prediction method
is left for future research.
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